UK biopharma company Circassia has raised £60 million funding for the final stage of development of its anti-allergy products. The …
A number of late stage failures from British biotech firms have left a looming question mark over the future of …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

